Michael A. Metzger, Chief Executive Officer at Syndax Pharmaceuticals Inc (SNDX), sold 66,258 shares at $25.01 ($1.7M) on 2022-10-03, disclosed to the SEC on 2022-10-04.
Open-market sale of $1.7M SNDX by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.02 | 29,606 | $741K | 44.7% |
| 2 | $25.02 | 29,606 | $741K | 44.7% |
| 3 | $25.01 | 2,883 | $72K | 4.3% |
| 4 | $25.01 | 2,883 | $72K | 4.3% |
| 5 | $25.02 | 1,280 | $32K | 1.9% |
| Total | $25.02 avg | 66,258 |
| $1.7M |
| 100% |
| Filing → |
| SNDX | SELL | 2026-02-10 | $361K | — | Filing → |
| SNDX | SELL | 2026-02-06 | $153K | — | Filing → |
| SNDX | SELL | 2025-09-08 | $5.2M | — | Filing → |